Evidence map›Paper›PMID 42088481›Full record

ArticleSexual medicine2026

Development of a clinical scoring system to predict response to low-intensity shock wave therapy in clinically diagnosed vasculogenic erectile dysfunction: a prospective, non-randomized, single-arm, interventional study.

Hakan Anıl, Ali Yıldız, Ayşe Nur Topuz, Mehmet Vehbi Kayra, Sinan Sözütok, Adem Altunkol, Ergün Alma, Mustafa Topuz, Yıldırım Bayazıt

Abstract read
In one paragraph

Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hakan AnılDepartment of Urology, University of Health Sciences, Adana City Training and Research Hospital, Adana, 01230, Turkey.ORCID https://orcid.org/0000-0002-6333-0213
Ali YıldızDepartment of Urology, Faculty of Medicine, Istanbul Okan University, Istanbul, 34959, Turkey.ORCID https://orcid.org/0000-0003-0293-9989
Ayşe Nur TopuzDepartment of Family Medicine, Cukurova University, Adana, 01130, Turkey.ORCID https://orcid.org/0000-0003-0970-228X
Mehmet Vehbi KayraDepartment of Urology, Baskent University School of Medicine, Adana Dr. Turgut Noyan Medical and Research Center, Adana, 01250, Turkey.ORCID https://orcid.org/0000-0002-7349-9952
Sinan SözütokDepartment of Interventional Radiology, Medical Park Seyhan Hospital, Adana, 01140, Turkey.ORCID https://orcid.org/0000-0003-3626-2312
Adem AltunkolDepartment of Urology, University of Health Sciences, Adana City Training and Research Hospital, Adana, 01230, Turkey.ORCID https://orcid.org/0000-0002-9300-3694
Ergün AlmaDepartment of Urology, University of Health Sciences, Adana City Training and Research Hospital, Adana, 01230, Turkey.ORCID https://orcid.org/0000-0003-2633-5274
Mustafa TopuzDepartment of Cardiology, Faculty of Medicine, Istanbul Aydın University, Istanbul, 34295, Turkey.ORCID https://orcid.org/0000-0002-6323-212X
Yıldırım BayazıtDepartment of Urology, Medical Park Seyhan Hospital, Adana, 01140, Turkey.ORCID https://orcid.org/0000-0001-7598-9667

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Erectile dysfunction (ED) is a prevalent condition, with vasculogenic ED being the most common subtype, primarily related to endothelial dysfunction and cardiovascular risk factors. Low-intensity extracorporeal shock wave therapy (Li-ESWT) has emerged as a promising non-invasive treatment option. However, predictors of treatment response remain poorly defined. Aim: To identify clinical and vascular predictors of treatment success following Li-ESWT in patients with vasculogenic ED and to develop a novel, practical, and non-invasive scoring system to predict therapeutic response. Methods: This prospective study included 219 men aged 18-80 years with vasculogenic ED between January 2024 and January 2025. All patients underwent Li-ESWT (18 000 pulses over 3 weeks). Clinical and vascular parameters, including age, ED duration, body mass index, presence of cardiovascular risk factors, diabetes mellitus (DM), carotid intima-media thickness (cIMT), flow-mediated dilation rate (FMD), and prior phosphodiesterase type 5 inhibitor (PDE5i) response, were recorded. Treatment success at 6 months was defined as an increase of ≥1 point in the erection hardness score or ≥5 points in the International Index of Erectile Function-5 EF. Outcomes: The primary outcome was treatment success at 6 months after Li-ESWT. Secondary outcomes included the development and validation of a predictive scoring system. Results: Treatment success rate was 66.2% (145/219). Independent predictors of treatment success were absence of DM (odds ratio [OR] = 2.67, Clinical Implications: This scoring system may help clinicians identify patients most likely to benefit from Li-ESWT, optimize patient selection, and improve individualized treatment strategies in vasculogenic ED. Strengths & Limitations: The study is strengthened by its prospective design, relatively large sample size, and inclusion of vascular function parameters (FMD, cIMT). Limitations include the lack of external validation and the absence of penile Doppler ultrasound confirmation in all patients. Conclusion: This study identified key demographic and vascular predictors of Li-ESWT response and introduces a novel, non-invasive clinical scoring system with strong predictive accuracy. This tool may enhance treatment personalization and support clinical decision-making in the management of ED.

Indexed as

clinical scoring systemerectile dysfunctionflow-mediated dilationlow-intensity extracorporeal shock wave therapypredictive factors

Identifiers

PMID42088481
PMCPMC13137323

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.